High-Cost Medicines in Thailand: A Global Perspective and Policy Recommendations

By Staff Writer

November 15, 2023

The Rising Cost of Medical Interventions

Novel medical interventions have emerged from scientific advancements, offering better quality and extended life for patients with life-threatening conditions. These interventions include gene therapies and tissue-engineered medicines that target various cancers, rare, and ultra-rare diseases. However, the medicines come with an extremely high cost. In 2022, the top ten most expensive medicines ranged from USD 600,000 to over USD 3.5 million per dose. This high cost puts a significant financial burden on households. Consequently, it can reduce, delay, or even deny access to potentially life-saving care. 

The Dilemma of High-Cost Medicines

There is currently no universally agreed-upon definition of high-cost medicine. Medicines often get described as those whose Incremental Cost-Effectiveness Ratio (ICER) goes beyond the public’s willingness-to-pay threshold for a Quality-Adjusted Life Year (QALY). Including these medicines in a public health insurance scheme’s benefits package means a high opportunity cost for a health system. If we increase the budget for public purchase, it results in withdrawing resources from private consumption through taxation or other methods. 

The Thai Approach to High-Cost Medicines

Thailand, an upper middle-income country in Southeast Asia, uses Health Technology Assessment (HTA), including cost-effectiveness analysis, to guide the development of its pharmaceutical benefits package, the National List of Essential Medicine (NLEM). Over the years, there has been increasing pressure to include medicines deemed cost-ineffective. A study was therefore commissioned to provide recommendations for the management of such medicines as part of the Universal Coverage Scheme (UCS) Benefit Package (UCBP).



International Experiences and Recommendations

The study revealed that countries have established alternative mechanisms for reimbursing high-cost medicines. These mechanisms require particular eligibility criteria to be met, such as disease severity, rarity, the effectiveness of medicines, treatment of a life-threatening condition, and the absence of alternative treatment options. The study also proposed a framework for reimbursing high-cost medicines in Thailand, which involves creating a new sub-category, “E3”, for the NLEM to access high-cost medicine under the benefit package.

Conclusion and Key Message

Public health insurance schemes should only reimburse high-cost medicines when they are cost-effective. Countries may consider reimbursing non-cost-effective high-cost medicines only when they save lives or lack alternative treatment options.  Monitoring and evaluation of implementation arrangements will be critical for assessing the impact of these programmes.

Reference url

Recent Posts

drug price transparency
     

Impending Net Drug Price Transparency Regulation in the U.S.

💡 Are you ready for a potential game-changer in drug pricing transparency?

CMS Administrator Mehmet Oz has hinted at a new rule aimed at enforcing stricter disclosures for drug prices, requiring healthcare companies to reveal actual transaction costs. This could reshape how price transparency is managed across the industry and challenge pharmacy benefit managers to rethink rebate practices.

Curious about how this will impact healthcare economics and what it means for drug affordability? Dive into the article for all the insights!

#SyenzaNews #healthcare #HealthEconomics

Sword Health mental health
         

How Does Mind’s AI-Driven Mental Healthcare Transform Care?

🤔 Are we ready to embrace AI in mental health care?

Sword Health has just secured €34.6 million to launch **Mind**, an innovative AI-powered mental health solution, blending licensed clinicians with continuous monitoring through wearables. This strategic expansion aims to address the pressing global mental health crisis while promoting personalized and proactive care models. 🌍🧠

Dive into how Sword Health is revolutionizing healthcare and bridging the gap between technology and clinical expertise.

#SyenzaNews #HealthTech #AIinHealthcare #DigitalTransformation

transparency in industry partnerships
   

Transparency in Industry Partnerships: Building Trust

🔍 How does transparency in industry partnerships impact patient care?

In the evolving landscape of healthcare, EFPIA’s mandatory disclosure requirements for financial interactions underscore the vital role of transparency in fostering trust and collaboration. By detailing financial transfers to healthcare professionals and organizations, the European Disclosure Gateway facilitates informed decision-making and strengthens relationships between stakeholders.

Have a look at the article to explore how these initiatives not only enhance public confidence but also drive innovation in treatments!

#SyenzaNews #HealthcareInnovation #HealthEconomics #innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.